Beyond Weight Loss
Background: Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) have transformed treatment for higher weight and diabetes. Because they also influence appetite and reward processes, these medications may shape eating behaviours, emotions, and body image, raising new challenges for eating disorder (ED) research and clinical care. This narrative review synthesises emerging evidence on the ...
Abstract Glucagon-like peptide-1 ( GLP-1 ) receptor agonists (RAs) have become central in managing obesity and type 2 diabetes, primarily through appetite suppression and metabolic regulation. This review explores the mechanisms underlying GLP-1 RA-induced weight loss, focusing on central and peripheral pathways.
Mechanisms of GLP
Multiple studies reviewed in this article document the diverse effects of these drugs on the glucagon-like peptide-1 receptors that are widely expressed in the human body, including the nervous system modulating appetite , the gastrointestinal tract modifying gastric emptying, and lipid metabolism regulation leading to reduction in fat deposition.
Gastrointestinal effects of GLP
The availability of glucagon-like peptide-1 ( GLP-1 ) receptor agonists (RAs) such as liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide coagonist (tirzepatide) represents a paradigm shift in the management of both type 2 diabetes and obesity. There is now considerable attention, including in the public media, on the effect of both long-acting and short ...
Abstract Glucagon-like peptide 1 ( GLP-1 ) is a cleavage product of the pre-proglucagon gene which is expressed in the α-cells of the pancreas, the L-cells of the intestine, and neurons located in the caudal brainstem and hypothalamus. GLP-1 is of relevance to appetite and weight maintenance because it has actions on the gastrointestinal tract as well as the direct regulation of appetite . It ...
The Efficacy of GLP
Objective The present systematic review aims to summarize the currently available evidence of the impact of GLP-1 analogues on appetite , gastric emptying, taste sensitivity, and food preferences among adults with obesity without other chronic diseases.
The advent of GLP-1 receptor agonists represents a milestone in the treatment of diabetes and obesity, but it also presents a challenge in balancing the drive for innovation with the need for patient safety.
Key Details About Assessment Of Glp-1 Receptor In Inhibiting Appetite
Here we provide a targeted synthesis of recent developments in the field of GLP-1 neurobiology, highlighting studies which have advanced our understanding of how GLP-1 signaling modulates eating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.
GLP-1 agonists are a type of medication you might need to take if you have type 2 diabetes. They are also known as GLP-1 analogues, GLP-1 RAs and incretin mimetics.
